Predicted protein targets (top 7)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MRGPRX2 | Q96LB1 | 4/20 | 1.00 |
| ▸ | OPRM1 | P35372 | 9/20 | 0.62 |
| ▸ | OPRD1 | P41143 | 9/20 | 0.61 |
| ▸ | OPRK1 | P41145 | 7/20 | 0.61 |
| ▸ | SLC22A1 | O15245 | 1/20 | 0.61 |
| ▸ | ADRA2A | P08913 | 1/20 | 0.61 |
| ▸ | ARRB1 | P49407 | 1/20 | 0.61 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL29583693 | 1.00 | MRGPRX2 (1.00) | MRGPRX2OPRM1OPRD1OPRK1SLC22A1 | |
| SCHEMBL29449917 | 1.00 | MRGPRX2 (1.00) | MRGPRX2OPRM1OPRD1OPRK1SLC22A1 | |
| Hydrochloric Acid SCHEMBL27754570 | 0.99 | MRGPRX2 (0.98) | MRGPRX2OPRM1OPRD1OPRK1SLC22A1 | |
| Methoxymethane SCHEMBL27466715 | 0.97 | MRGPRX2 (0.94) | MRGPRX2OPRM1OPRD1OPRK1SLC22A1 | |
| SCHEMBL10527174 | 0.90 | MRGPRX2 (0.82) | MRGPRX2OPRM1OPRD1OPRK1SLC22A1 | |
| SCHEMBL8362208 | 0.90 | MRGPRX2 (0.81) | MRGPRX2OPRM1OPRD1OPRK1SLC22A1 | |
| SCHEMBL8356924 | 0.88 | MRGPRX2 (0.79) | MRGPRX2OPRM1OPRD1OPRK1SLC22A1 | |
| SCHEMBL5108263 | 0.88 | MRGPRX2 (1.00) | MRGPRX2OPRM1OPRD1OPRK1 | |
| SCHEMBL29459625 | 0.88 | MRGPRX2 (1.00) | MRGPRX2OPRM1OPRD1OPRK1 | |
| Hydrochloric Acid SCHEMBL8168636 | 0.87 | MRGPRX2 (0.98) | MRGPRX2OPRM1OPRD1OPRK1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1091 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-12523669-B2 | Methods and systems for improved quality assurance for high-throughput analysis | LABORATORY CORPORATION OF AMERICA HOLDINGS (US) | 2026-01-13 | — | — | US | claimed |
| US-20250304722-A1 | ANTI-NALOXONE AND ANTI-NALTREXONE MONOCLONAL ANTIBODIES AND METHODS OF PRODUCTION AND USE THEREOF | SIEMENS HEALTHCARE DIAGNOSTICS INC. (US) | 2025-10-02 | — | — | US | claimed |
| US-12429484-B2 | Homogeneous enzyme immunoassay for keratinized structures | PSYCHEMEDICS CORPORATION (US) | 2025-09-30 | — | — | US | claimed |
| US-12385919-B2 | — | — | 2025-08-12 | — | — | US | claimed |
| US-12364430-B2 | Wearable device for continuous monitoring of user health for accurate clinical outcomes and wellness programs | KURANI HETAL B (US) | 2025-07-22 | — | — | US | claimed |
| CN-117654455-B | Purifying and extracting composition, kit and method for determining drugs and fentanyl drugs in biological sample | 宁波市疾病预防控制中心(宁波市健康教育与促进中心) | 2025-06-10 | — | — | CN | claimed |
| WO-2025111546-A1 | DEVELOPMENT OF BROAD-SPECTRUM ANTI-OPIOID VACCINES | BOARD OF TRUSTEES OF MICHIGAN STATE UNIVERSITY (US) | 2025-05-30 | — | — | WO | claimed |
| US-20250157623-A1 | WEARABLE DEVICE FOR CONTINUOUS MONITORING OF USER HEALTH FOR ACCURATE CLINICAL OUTCOMES AND WELLNESS PROGRAMS | KURANI HEMAL B (US) | 2025-05-15 | — | — | US | claimed |
| US-20250130211-A1 | METHOD OF SCREENING NEW PSYCHOACTIVE SUBSTANCE AND PLATFORM THEREOF | NATIONAL TAIWAN UNIVERSITY (TW) | 2025-04-24 | — | — | US | claimed |
| EP-3983127-B1 | PLASMA SEPARATION AND SAMPLE METERING DEVICE AND METHODS OF USE RELATED THERETO | SIEMENS HEALTHCARE DIAGNOSTICS INC (US) | 2025-04-23 | — | — | EP | claimed |
| EP-0649465-B1 | MORPHINONE REDUCTASE FOR THE PREPARATION OF HYDROMORPHONE AND HYDROCODONE | MACFARLAN SMITH LTD (GB) | 2002-07-24 | — | — | EP | claimed |
| EP-1027609-A2 | METHOD FOR DETERMINATION OF DRUGS OF ABUSE IN BIOLOGICAL SAMPLES | Varian, Inc. (US) | 2000-08-16 | — | — | EP | claimed |
| WO-1999022244-B1 | METHOD FOR DETERMINATION OF DRUGS OF ABUSE IN BIOLOGICAL SAMPLES | VARIAN INC (US) | 1999-09-10 | — | — | WO | claimed |
| WO-1999022244-A2 | METHOD FOR DETERMINATION OF DRUGS OF ABUSE IN BIOLOGICAL SAMPLES | VARIAN, INC. (US) | 1999-05-06 | — | — | WO | claimed |
| US-5571685-A | POLYPEPTIDES IN SYNTHESIS OF ANALGESICS | MACFARLAN SMITH LIMITED (GB) | 1996-11-05 | — | — | US | claimed |
| EP-0471740-B1 | ENZYMES AND THEIR USE IN DRUG DETECTION | BRITISH TECH GROUP (GB) | 1995-08-09 | — | — | EP | claimed |
| US-5387515-A | Oxidation in the presence of the enzyme and cofactor nadp | BRITISH TECHNOLOGY GROUP LIMITED (GB) | 1995-02-07 | — | — | US | claimed |
| US-5298414-A | Polypeptides, oxidation for detection | BRITISH TECHNOLOGY GROUP LIMITED (GB) | 1994-03-29 | — | — | US | claimed |
| EP-0471740-A1 | ENZYMES AND THEIR USE IN DRUG DETECTION. | NAT RES DEV (GB) | 1992-02-26 | — | — | EP | claimed |
| WO-1990013634-A2 | ENZYMES AND THEIR USE IN DRUG DETECTION | NATIONAL RESEARCH DEVELOPMENT CORPORATION (GB) | 1990-11-15 | — | — | WO | claimed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20250304722-A1 | ANTI-NALOXONE AND ANTI-NALTREXONE MONOCLONAL ANTIBODIES AND METHODS OF PRODUCTION AND USE THEREOF | OPRK1, OPRM1, OPRL1 | MRGPRX2 1670/4885OPRM1 2/4885OPRD1 4/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.